Hydralazine
Hydralazine is a direct vasodilator, a medicine taken by mouth that the label says apparently lowers blood pressure by relaxing the muscle in blood vessel walls. The US label read, for generic hydralazine hydrochloride tablets, lists essential hypertension, alone or as an adjunct (an add-on to other treatment). The label says the precise mechanism of action is not fully understood.
Also called Hydralazine hydrochloride
- Drug
- In this atlas
Overview
Technical summary
RxNorm ingredient 5470 (hydralazine hydrochloride is 82027); UNII FD171B778Y is the UNII of the hydrochloride salt that the label gives, so it is a broad match. MeSH descriptor D006830 is Hydralazine. RxClass lists the FDA established pharmacologic class Arteriolar Vasodilator, the class the direct vasodilators page records for minoxidil; the record is filed under that page on that evidence, and the page gained the alias Arteriolar vasodilator for it. The label read is the Chartwell RX, LLC generic tablet label, application ANDA086242, effective 2025-12-10 in openFDA, the label the class page already uses. The UNII and application number come from the openFDA record as read on 2026-11-09; the record read again on 2026-11-18 has the same effective date but no longer carries those fields. The plan row's label (set id 024ac6b8) was not read, and the combination products that contain hydralazine were not read. This page records the label indication and the mechanism sentences only: no trial result and no dose is given.
About this drug
- Level
- Substance
- Mechanism
- The label says the precise mechanism of action is not fully understood and that hydralazine apparently lowers blood pressure by a peripheral vasodilating effect through a direct relaxation of vascular smooth muscle.
Classification codes
-
FD171B778Y
Claims and evidence
Context People with essential hypertension, as described in the US label of generic hydralazine hydrochloride tablets
- Recipient
- Recipient not specified
- Population
- Patients with essential hypertension, as the indications section of the label states. The label passages read do not state an age range.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Not stated in the label passages read
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
- Included
- Patients with essential hypertension
- Excluded
- None stated
The US label of hydralazine hydrochloride tablets (Chartwell RX, LLC, application ANDA086242; the version dated 2025-12-10 in openFDA) lists essential hypertension, alone or as an adjunct. It says the precise mechanism of action is not fully understood, and that hydralazine apparently lowers blood pressure by a peripheral vasodilating effect through a direct relaxation of vascular smooth muscle.
Applies to Recipient not specified People with essential hypertension, as described in the US label of generic hydralazine hydrochloride tablets
- Certainty method
- Not assessed
- Limitations
- This claim records what one US label says the medicine is indicated for and how it describes the medicine. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label is for a generic product; the brand label and the combination products that contain hydralazine were not read. The label passages read state no age range except where the claim says adults. Contraindications, warnings, interactions, use in pregnancy and in children, and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-18
- Next evidence check due
- Not scheduled
Sources and citations (4)
-
- Locator
- results[0].openfda.application_number[0]
- How it applies
- Application number of the label read.
- Retrieved
- Source effective date
- 2025-12-10
- Source state
- Current
- Version fingerprint
4e1cb223bca6888418cbbac330a7ba3a63b8a95f8e0cc0a461a97bfdf2be1fa0- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read.
- Retrieved
- Source effective date
- 2025-12-10
- Source state
- Current
- Version fingerprint
4e1cb223bca6888418cbbac330a7ba3a63b8a95f8e0cc0a461a97bfdf2be1fa0- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0]
- How it applies
- Label passage quoted in the research quote table (HYD-LB-04).
- Retrieved
- Source effective date
- 2025-12-10
- Source state
- Current
- Version fingerprint
4e1cb223bca6888418cbbac330a7ba3a63b8a95f8e0cc0a461a97bfdf2be1fa0- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].clinical_pharmacology[0]
- How it applies
- Label passage quoted in the research quote table (HYD-LB-05, HYD-LB-06).
- Retrieved
- Source effective date
- 2025-12-10
- Source state
- Current
- Version fingerprint
4e1cb223bca6888418cbbac330a7ba3a63b8a95f8e0cc0a461a97bfdf2be1fa0- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact FDA label lists essential hypertension, alone or as an adjunct, as the indication: Hypertension (high blood pressure)
Applies to Recipient not specified People with essential hypertension, as described in the US label of generic hydralazine hydrochloride tablets
The US label of hydralazine hydrochloride tablets (Chartwell RX, LLC, application ANDA086242; the version dated 2025-12-10 in openFDA) lists essential hypertension, alone or as an adjunct. It says the precise mechanism of action is not fully understood, and that hydralazine apparently lowers blood pressure by a peripheral vasodilating effect through a direct relaxation of vascular smooth muscle.Limitations. This claim records what one US label says the medicine is indicated for and how it describes the medicine. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label is for a generic product; the brand label and the combination products that contain hydralazine were not read. The label passages read state no age range except where the claim says adults. Contraindications, warnings, interactions, use in pregnancy and in children, and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
Record details
- Record id
cardio:hydralazine- Content hash
a720f56047a97697bf4062548a20b76ce78b6557d6c413051cbce1013ae25590